CRT-D replacement strategy: results of the BioCONTINUE study.
Cardiac resynchronization therapy (CRT)
ICD replacement
Implantable cardioverter-defibrillator (ICD)
Primary ICD indications
Sudden death
Ventricular arrhythmia
Journal
Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
01
09
2022
accepted:
25
11
2022
medline:
12
7
2023
pubmed:
3
12
2022
entrez:
2
12
2022
Statut:
ppublish
Résumé
In patients with cardiac resynchronization therapy defibrillators (CRT-Ds), the need for implantable cardioverter-defibrillator (ICD) back-up may be questionable at time of CRT-D replacement (REP) if ICD implant criteria are no longer met due to an improved left ventricular ejection fraction (LVEF) and if no major ventricular arrhythmic event (VAE) occurred during the CRT-D lifetime. The aim of our study was to assess the relevance of ICD back-up and predictors of VAE after REP in primary prevention CRT-D patients. The prospective, observational, international BioCONTINUE study investigated the rate of patients with at least 1 sustained VAE (sVAE) post-REP and searched for predictive factors of sVAE. Two hundred seventy-six patients (70 ± 10 years, 77% men, mean LVEF 40.6 ± 12.6%) were followed for 28.4 ± 10.2 months. The rate of patients with sVAE was 8.3%, 10.3%, and 21.2% at 1, 2, and 4 years post-REP. Patients without persistent ICD indication at REP still had a sVAE rate of 5.7% (95% CI 2.3-11.5%) at 2 years. In multivariate analysis, predictive factors of subsequent sVAE were (i) persistent ICD indication (hazard ratio (HR) 3.6; 95% CI 1.6-8.3; p = 0.003); (ii) 64-72 years of age as compared to ≥ 79 years (HR 3.7; 95% CI 1.4-9.7; p = 0.008); and (iii) ischemic heart disease (HR 4.4; 95% CI 2.1-9.3; p < 0.0001). The risk of sVAE (21.2% at 4 years post-REP) depends on age, ischemic heart disease, and ICD indication at the time of REP. A non-trivial risk of sVAE remains in patients without persistent ICD indication. NCT02323503.
Sections du résumé
BACKGROUND
BACKGROUND
In patients with cardiac resynchronization therapy defibrillators (CRT-Ds), the need for implantable cardioverter-defibrillator (ICD) back-up may be questionable at time of CRT-D replacement (REP) if ICD implant criteria are no longer met due to an improved left ventricular ejection fraction (LVEF) and if no major ventricular arrhythmic event (VAE) occurred during the CRT-D lifetime. The aim of our study was to assess the relevance of ICD back-up and predictors of VAE after REP in primary prevention CRT-D patients.
METHODS
METHODS
The prospective, observational, international BioCONTINUE study investigated the rate of patients with at least 1 sustained VAE (sVAE) post-REP and searched for predictive factors of sVAE.
RESULTS
RESULTS
Two hundred seventy-six patients (70 ± 10 years, 77% men, mean LVEF 40.6 ± 12.6%) were followed for 28.4 ± 10.2 months. The rate of patients with sVAE was 8.3%, 10.3%, and 21.2% at 1, 2, and 4 years post-REP. Patients without persistent ICD indication at REP still had a sVAE rate of 5.7% (95% CI 2.3-11.5%) at 2 years. In multivariate analysis, predictive factors of subsequent sVAE were (i) persistent ICD indication (hazard ratio (HR) 3.6; 95% CI 1.6-8.3; p = 0.003); (ii) 64-72 years of age as compared to ≥ 79 years (HR 3.7; 95% CI 1.4-9.7; p = 0.008); and (iii) ischemic heart disease (HR 4.4; 95% CI 2.1-9.3; p < 0.0001).
CONCLUSIONS
CONCLUSIONS
The risk of sVAE (21.2% at 4 years post-REP) depends on age, ischemic heart disease, and ICD indication at the time of REP. A non-trivial risk of sVAE remains in patients without persistent ICD indication.
CLINICAL TRIAL REGISTRATION
BACKGROUND
NCT02323503.
Identifiants
pubmed: 36459310
doi: 10.1007/s10840-022-01440-5
pii: 10.1007/s10840-022-01440-5
doi:
Banques de données
ClinicalTrials.gov
['NCT02323503']
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1201-1209Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Cazeau S, Leclercq C, Lavergne T, Walker S, Varma C, Linde C, et al. Effects of multisite biventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med. 2001;344:873–80.
doi: 10.1056/NEJM200103223441202
pubmed: 11259720
Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–49.
doi: 10.1056/NEJMoa050496
pubmed: 15753115
Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–50.
doi: 10.1056/NEJMoa032423
pubmed: 15152059
Manfredi JA, Al-Khatib SM, Shaw LK, Thomas L, Fogel RI, Padanilam B, et al. Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias. Circ Arrhythm Electrophysiol. 2013;6:257–64.
doi: 10.1161/CIRCEP.112.000214
pubmed: 23443618
Van Welsenes GH, van Rees JB, Borleffs CJW, Cannegieter SC, Bax JJ, van Erven L, et al. Long-term follow up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace. 2011;13:389–94.
doi: 10.1093/europace/euq494
pubmed: 21208947
Alsheikh-Ali AA, Homer M, Maddukuri PV, Kalsmith B, Estes NAM III, Link MS. Time-dependence of appropriate implantable defibrillator therapy in patients with ischemic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19:784–9.
doi: 10.1111/j.1540-8167.2008.01111.x
pubmed: 18284493
Al-Khatib SM, Friedman DJ, Sanders GD. When is it safe not to re-implant an implantable cardioverter defibrillator at the time of battery depletion? Card Electrophysiol Clin. 2018;10:137–44.
doi: 10.1016/j.ccep.2017.11.014
pubmed: 29428135
pmcid: 6861160
Sebag FA, Lellouche N, Chen Z, Tritar A, O’Neill MD, Gill J, et al. Positive response to cardiac resynchronization therapy reduces arrhythmic events after elective generator change in patients with primary prevention CRT-D. J Cardiovasc Electrophysiol. 2014;12:1368–75.
doi: 10.1111/jce.12496
Kini V, Soufi MK, Deo R, Epstein AE, Bala R, Riley M, et al. Appropriateness of primary prevention implantable cardioverter-defibrillators at the time of generator replacement: are indications still met? J Am Coll Cardiol. 2014;63:2388–94.
doi: 10.1016/j.jacc.2014.03.025
pubmed: 24727249
pmcid: 6007855
Kawata H, Hirai T, Doukas D, Hirai R, Steinbrunner J, Wilson J, et al. The occurrence of implantable cardioverter defibrillator therapies after generator replacement in patients who no longer meet primary prevention indications. J Cardiovasc Electrophysiol. 2016;27:724–9.
doi: 10.1111/jce.12961
pubmed: 26915696
Narducci ML, Biffi M, Ammendola E, Vado A, Campana A, Potenza DR, et al. Appropriate implantable cardioverter-defibrillator interventions in cardiac resynchronization therapy-defibrillator (CRT-D) patients undergoing device replacement: time to downgrade from CRT-D to CRT-pacemaker? Insights from real-world clinical practice in the DECODE CRT-D analysis. Europace. 2018;20:1475–83.
doi: 10.1093/europace/eux323
pubmed: 29186401
Yuyun MF, Erqou SA, Peralta AO, Hoffmeister PS, Yarmohammadi H, Echouffo Tcheugui JB, et al. Risk of ventricular arrhythmia in cardiac resynchronization therapy responders and super-responders: a systematic review and meta-analysis. Europace. 2021;23:1262–74.
doi: 10.1093/europace/euaa414
pubmed: 33496319
Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device- based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2013;127:e283-352.
doi: 10.1161/CIR.0b013e318276ce9b
pubmed: 23255456
Wu KC, Gerstenblith G, Guallar E, Marine JE, Dalal D, Cheng A, et al. Combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging. 2012;5:178–86.
doi: 10.1161/CIRCIMAGING.111.968024
pubmed: 22267750
pmcid: 3330427
Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42:3427–520.
doi: 10.1093/eurheartj/ehab364
pubmed: 34455430
Zegard A, Okafor O, de Bono J, Kalla M, Lencioni M, Marshall H, et al. Greyzone myocardial fibrosis and ventricular arrhythmias in patients with a left ventricular ejection fraction >35. Europace. 2022;24:31–9.
doi: 10.1093/europace/euab167
pubmed: 34379762
Russo AM, Stainback RF, Bailey SR, Epstein AE, Heidenreich PA, Jessup M, et al. ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy. Heart Rhythm. 2013;10:1318–68.
doi: 10.1016/j.hrthm.2013.01.008